Hypoxia induicible factor-1 alpha (HIF-1α) is a key transcription factor in cancer progression
and target therapy in cancer. HIF-1α acts differently depending on presence or absence of …

Abstract Hypoxia-inducible factor-1 (HIF-1) has been recognized as an important cancer
drug target. Many recent studies have provided convincing evidences of strong correlation …

Background This review focuses on exosomes derived from various cancer cells. The review
discusses the possibility of differentiating macrophages in alternatively activated anti …

Insufficient tissue oxygenation, or hypoxia, contributes to tumor aggressiveness and has a
profound impact on clinical outcomes in cancer patients. At decreased oxygen tensions …

The responses of patients to tumor therapies vary due to tumor heterogeneity. Tumor
stratification has been attracting increasing attention for accurately distinguishing between …

Tumor hypoxia is a well-established biological phenomenon that affects the curability of
solid tumors, regardless of treatment modality. Especially for head and neck cancer patients …

Background Clinical prognostic groupings for localised prostate cancers are imprecise, with
30–50% of patients recurring after image-guided radiotherapy or radical prostatectomy. We …

In countries with the best cancer outcomes, approximately 60% of patients receive
radiotherapy as part of their treatment, which is one of the most cost-effective cancer …

Metastasis to bone frequently occurs in majority of patients with advanced breast cancer and
prostate cancer, leading to devastating skeletal-related events and substantially reducing …

Radiotherapy, an important treatment modality in oncology, kills cells through induction of
oxidative stress. However, malignant tumors vary in their response to irradiation as a …